New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;BSX;MDT;JNJ;INTC;JNJ;INTC;VRTX;COV;VRTX;COV;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 14, 2014
12:43 EDTMDT, COVMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTMDT, COVMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
November 13, 2014
18:07 EDTCOVCovidien' VenaSeal closure system shows positive results
Covidien announced the six-month results of the VeClose pivotal study of the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal system to that of the ClosureFast endovenous radiofrequency ablation catheter. Covidien's ClosureFast catheter is an endovenous radiofrequency ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal system is not approved and currently limited to investigational use in the U.S. At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal system compared to 95.6% of patients treated with the ClosureFast catheter. The closure rate at six months was 98.9% and 94.3%.
17:10 EDTBSXBoston Scientific S-ICD System receives favorable coding, payment designations
Subscribe for More Information
16:35 EDTMDTMedtronic study reveals heart rhythm disorders in patients with ESRD
Subscribe for More Information
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
14:50 EDTMDTLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTMDTLonestar capital to shut down, DJ reports
Subscribe for More Information
13:27 EDTCOV, MDTMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
November 12, 2014
15:08 EDTINTCEarnings Preview: Cisco reports amid analyst debate on break-up potential
Subscribe for More Information
14:08 EDTINTCIntel reports 427.7K share position in Rocket Fuel
Subscribe for More Information
07:27 EDTBSXNorth American Spine Society to hold annual meeting
Subscribe for More Information
07:23 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 23, December is at 20, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
November 11, 2014
07:24 EDTCOV, MDTMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
November 10, 2014
15:54 EDTCOVAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:10 EDTMDTMedtronic announces Japanese approval, launch of Evera MRI SureScan ICD
Subscribe for More Information
08:36 EDTCOVBSD Medical names Clint Carnell as president and CEO
Subscribe for More Information
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use